SEC Form 4 · accession 0001415889-16-006297
Vistagen Therapeutics, Inc. · VTGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shawn Singh
Officer — CHIEF EXECUTIVE OFFICER · Director
Period of report
Jun 19, 2016
Accepted (ET)
Jun 21, 2016 · 9:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411685
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $3.49 | Jun 19, 2016 | A | 200,000 | A | — | Jun 19, 2026 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1The Reporting Person's ability to exercise 75,000 of the options reported herein is conditioned upon stockholder approval of an amendment to the Issuer's 2008 Stock Incentive Plan.
- F225% of the shares subject to the option shall vest on the one year anniversary of the Grant Date and 1/48th of the shares subject to the option shall vest monthly every month thereafter until all awarded shares are fully vested.